clinical trial · NCT07502560
A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland
Herpes ZosterRecombinant zoster vaccinePlacebo
brief summary
The purpose of this study is to evaluate the effect of the recombinant zoster vaccine on the risk of new diagnosis of dementia among adults aged 76 years or older in Finland. Participants will be enrolled and randomized in a 3:1 ratio to receive either recombinant zoster vaccine or placebo.
started
Mar 31, 2026
primary completion
Apr 1, 2030
completion
Mar 31, 2037
last updated
May 12, 2026
official title
A Randomized, Placebo Controlled, Observer-blind, Phase IV Pragmatic Trial to Evaluate the Effect of Recombinant Zoster Vaccine (Shingrix) on Incident Dementia Diagnosis in an Older Adult Population Aged ≥76 Years in Finland
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol